Your browser doesn't support javascript.
loading
Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection.
Vietri, Maria Teresa; D'Elia, Giovanna; Caliendo, Gemma; Passariello, Luana; Albanese, Luisa; Molinari, Anna Maria; Angelillo, Italo Francesco.
Afiliación
  • Vietri MT; Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via L. De Crecchio, 80138 Naples, Italy; U.O.C. Clinical and Molecular Pathology, A.O.U. University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. Electronic address: mariateresa.vietri@unicampania.it.
  • D'Elia G; U.O.C. Clinical and Molecular Pathology, A.O.U. University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. Electronic address: giovanna.delia@policliniconapoli.it.
  • Caliendo G; U.O.C. Clinical and Molecular Pathology, A.O.U. University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. Electronic address: gemma.caliendo@unicampania.it.
  • Passariello L; U.O.C. Clinical and Molecular Pathology, A.O.U. University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. Electronic address: luana.passariello@studenti.unicampania.it.
  • Albanese L; U.O.C. Clinical and Molecular Pathology, A.O.U. University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. Electronic address: luisa.albanese@unicampania.it.
  • Molinari AM; Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via L. De Crecchio, 80138 Naples, Italy; U.O.C. Clinical and Molecular Pathology, A.O.U. University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. Electronic address: annamaria.molinari@unicampania.it.
  • Angelillo IF; Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Via L. Armanni 5, 80138 Naples, Italy. Electronic address: italof.angelillo@unicampania.it.
Vaccine ; 40(39): 5726-5731, 2022 09 16.
Article en En | MEDLINE | ID: mdl-36041940
In the present study, immunogenicity data in 61 vaccinated healthcare workers (HCWs) either infection naïve (naïve HCWs) or with infection of Delta and/or Omicron COVID-19 (experienced HCWs) were evaluated up to 270 days after the second dose of BNT162b2 vaccine and up to 90 days after a booster dose. A decrease in antibody levels at 270 days following administration of the second dose (p = 0.0335) was observed, although values did not fall below the positivity threshold (33.8 BAU/ml). After booster vaccination, antibody levels increased after 30 days (p = 0.0486), with much higher values than after first and second vaccination. Antibody levels then decreased at 60 and 90 days after the booster dose. A comparison between mean antibody levels of naïve and experienced HCWs revealed higher values in experienced HCWs, resulting from both natural and vaccination-induced immunity. A total of 14.7% of HCWs contracted the Omicron virus variant after the vaccine booster, although none showed severe symptoms. These results support that a booster dose results in a marked increase in antibody response that subsequently decreases over time.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: Vaccine Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: Vaccine Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos